CJC-1295 DAC

CJC-1295 DAC is described as a long-acting analog of growth hormone–releasing hormone (GHRH). The protocol explains that the DAC (Drug Affinity Complex) modification enables reversible albumin binding, extending the peptide’s half-life to multiple days compared with minutes for typical GHRH analogs. Mechanistically, it binds GHRH receptors on pituitary somatotrophs and drives growth hormone release, which then raises IGF-1 (primarily hepatic) as a downstream mediator of many growth and metabolic effects. Importantly, the page notes that GH secretion remains pulsatile even with continuous stimulation, suggesting preservation of physiologic release patterns. The overall rationale presented is sustained GH/IGF-1 axis activation with less frequent dosing. The protocol frames potential outcomes in terms of body-composition shifts and recovery/anabolic signaling, while noting that tolerability issues are usually mild (e.g., injection-site reactions) with some users describing transient flushing, headache, or water retention—especially during titration.